Ariad Pharmaceuticals (ARIA) News Today → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free Aria Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineIDRx Appoints David P. Kerstein, M.D., as Chief Medical Officerfinance.yahoo.com - March 27 at 5:21 PMIDRx Strengthens Executive Team with Appointments of Tim Clackson, Ph.D., as CEO and Brad Dahms as CFO and CBOfinance.yahoo.com - March 12 at 8:42 AMWhat Is Donanemab? Eli Lilly’s Alzheimer’s Drug Gets Delayed Decision From FDAmsn.com - March 8 at 3:24 PMTakeda extends lease in Kendall Square through 2040bizjournals.com - March 4 at 4:08 PMIncyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Prioritiesfinance.yahoo.com - February 13 at 9:14 AMVeteran biotech entrepreneur Harvey Berger to lead startup Kojin Therapeuticsmsn.com - January 3 at 9:06 AMHarvey Berger leaves biotech 'sidelines' for new CEO gigbizjournals.com - January 3 at 9:06 AMBiogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatmentmsn.com - October 26 at 2:56 PMLeukemia Therapeutics Treatment Market Set to Achieve US$ 30,318.5 Million by 2033 at 7.1% CAGR | Future Market Insights Inc.benzinga.com - October 12 at 1:15 PMKickstarter’s new finance chief is ultra-extroverted—and she credits that trait to her success as a ‘people-centric CFO’fortune.com - September 6 at 9:48 AMChronic Lymphocytic Leukemia Treatment Global Market Report 2023finance.yahoo.com - August 24 at 5:49 PMAriad Stock Falls On Unusually High Volume (ARIA)thestreet.com - August 20 at 8:33 PMSecond Alzheimer’s drug to slow disease’s progression may be approved in the US this yearmsn.com - July 19 at 12:57 AMSecond Alzheimer's drug to slow disease's progression may be approved in the US this yearcbsnews.com - July 17 at 1:07 PMSarissa Capital Urges Alkermes Shareholders to Vote "FOR" Sarah Schlesinger and "WITHHOLD" Incumbent Director Richard Gaynorfinance.yahoo.com - June 28 at 8:14 AMActivist Pro Tip: Don’t Put Your Girlfriend on the Boardwashingtonpost.com - June 26 at 10:18 AMPonatinib Market Research | 2023-2030marketwatch.com - May 17 at 12:32 AMComprehensive Analysis of Cancer Treatment Drugs Market Trends and Growth 2023-2030marketwatch.com - May 16 at 2:32 PMIclusig Market Research | 2023-2030marketwatch.com - May 14 at 9:18 AMUterine Cancer Therapies and Diagnostic Market Forecast 2023-2030marketwatch.com - May 10 at 1:51 PMThe Global Targeted Drugs for NSCLC Market Size is expanding rapidly, with a CAGR of 12.2% from 2023 to 2030marketwatch.com - May 5 at 6:41 PMChronic Myeloid Leukemia (CML) Treatment Market 2023 [New Report forecast 2030] Current and Future Trendsmarketwatch.com - May 5 at 8:02 AMEli Lilly Surges After Alzheimer's Treatment Succeeds; Biogen Also Risesmsn.com - May 3 at 12:57 PMAcute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Analysis and Forecast to 2031marketwatch.com - May 3 at 12:57 PMCancer Drugs Market Applications and Types with Regional Analysis 2023-2031marketwatch.com - May 3 at 12:57 PMStomach Cancer Drugs Market (2023-2030) Rivalry Heats Up with New CAGR Statusmarketwatch.com - April 28 at 8:44 AMGlobal Gastric Cancer Drugs Market Report 2023: Increasing Number of Obesity Cases and the Smoking Population Drives Growthbenzinga.com - April 20 at 1:54 PM2023-2030 Chronic Myeloid Leukemia (CML) Treatment Market Size with Manufacturesmarketwatch.com - April 20 at 3:54 AM2023-2030 Ponatinib Market Size Detailed Report with Downstream Market Analysis | Research by Absolute Reportsmarketwatch.com - April 19 at 2:14 AMUnlock Vital Data on Ponatinib market: Financial Summary, Shareholding Patterns, and Revenue Mix with Predicted CAGR of 5.1% from 2023-2030marketwatch.com - April 12 at 7:15 PMChronic Myeloid Leukemia (CML) Treatment Market 2023 Size and Forecast to 2031marketwatch.com - April 9 at 12:57 AMIn-depth Cancer Treatment Drugs report provides key estimates for predicting a projected CAGR of 5.2%marketwatch.com - April 8 at 7:57 PMPonatinib Market Research Analysis 2023-2030marketwatch.com - April 7 at 8:56 AMBile Duct Cancer Drug Market Growing Demand and Trends 2023 to 2031marketwatch.com - March 29 at 10:44 AMAnti-Cancer Drug Market Size and Forecast till 2031marketwatch.com - March 27 at 9:54 AMGlobal Cancer Drugs Market 2023 Projection, Growth Rate and Emerging Trends Analysis to 2030 By VMReportsmarketwatch.com - March 26 at 1:57 PMIclusig Market Top Players and Forecast till 2031marketwatch.com - March 22 at 7:29 PMPonatinib Market Size 2023 to 2028 By Deployment, Growth Factor and Production costmarketwatch.com - March 14 at 8:11 AMThe Evolution of Bile Duct Cancer Drug Market 2023: Future Developments and Trends by 2028marketwatch.com - March 11 at 4:50 AM2023-2029 Anti-Cancer Drug Market Size and Latest Trends Analysis | Research Report by Absolute Reportsmarketwatch.com - March 10 at 6:41 PMGrowth Analysis on Proto-Oncogene Drgu Market Size 2023-2028 with Prominent Manufacturers | Research Report by Absolute Reportsmarketwatch.com - March 8 at 6:51 PMForecasting the Future of Chronic Myeloid Leukemia (CML) Treatment Market: Analysing Emerging Trends and Opportunities 2023-2028marketwatch.com - March 7 at 5:43 PMGlobal Targeted Drug EGFR RTK Inhibitors for NSCLC Market Opportunities, Business Statistics Research Report 2030 By VMReportsmarketwatch.com - March 4 at 4:25 PMGlobal Targeted Drugs for NSCLC Market Size Analysis, Share, Application, Opportunities Forecast to 2030 By VMReportsmarketwatch.com - March 4 at 4:25 PMGlobal Anti-Cancer Drug Market 2023 Industry Share, Analysis of Competitive Landscape and Forecast 2030 By VMReportsmarketwatch.com - March 4 at 4:28 AMGlobal Acute Lymphocytic / Lymphoblastic Leukemia Drugs Market Upcoming Trends, Opportunities by Types and Application to 2030 By VMReportsmarketwatch.com - March 1 at 9:33 AMIn Depth Research on Uterine Cancer Therapies and Diagnostic Market Report 2023-2029marketwatch.com - March 1 at 9:33 AMGlobal Proto-Oncogene Drgu Market Size 2023 Business Strategies, Growth Analysis, Regional Demand, 2030 Forecast Research Report By VMReportsmarketwatch.com - February 27 at 11:08 PMBile Duct Cancer Drug Market 2023 Size, Share, Growth, Analysis, Trends and Forecast to 2028marketwatch.com - February 27 at 8:22 AMChronic Myeloid Leukemia (CML) Treatment Market is Booming by Size, Revenue, Trend and Top Growing Companies 2023-2028marketwatch.com - February 22 at 10:54 AM Get Ariad Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARIA and its competitors with MarketBeat's FREE daily newsletter. Email Address These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy ARIA Media Mentions By Week ARIA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARIA News Sentiment▼0.000.41▲Average News Sentiment ARIA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARIA Articles This Week▼00▲ARIA Articles Average Week Get Ariad Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARIA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARIA) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHis win rate puts Warren Buffett to shame… Investing DailyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ariad Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
